Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention

Table 1 Characteristics of eradication trials included in Latin America

Ref.	Year	Country	Patients enrolled or randomized	Mean age ± SD (age range)	Patient population	Treatment arm(s)	Antibiotic duration (d)	Second antibiotic treatment	Eradi-cation success rate	Wait time (wk)	Diagnostic method(s)	Follow-up, yr	Study design and quality[17]
Morgan et al[22]	2013	6 countriesa	1463	(21-65)	Community populations	3 options:	Variable:	PPI + M + Bis + Tetrab	Total 77.4%	6-8	13C, CagA IgG	1	5
						PPI + A + C	14		82.20%
						PPI + A/PPI + A + M	5/5		76.50%
						PPI + A + C + M	5		73.60%
Silva et al[34]	2010	Brazil	150	46.7 (16-85)	Duodenal ulcer	PPI + A + C	7	PPI + Tetra + Furazolidone	92.50%	13	14C, H (RUT, PCR)	5	3
Mesquita et al[35]	2005	Brazil	50	49 ± 14 (> 18)	Duodenal ulcer	H2 + Bis + C	14	NA	100%	13	H (RUT, H and E)	3	2
Coelho et al[36]	1991	Brazil	48	40.4 (adults)	Duodenal ulcer	A + M + Furaz	5	NA	60.40%	8.5	14C	1.5	2
Rollan et al[37]	2000	Chile	111	38 (16-75)	Duodenal ulcer	2 options: H2 + A + M PPI + A + Tinidazole	14 14	Cross-over	Total 75.7% 79% 73%	4-6	14C, H (RUT, Warthin-S, PCR)	3	3
Figueroa et al[38]	1996	Chile	57	49.1 (16-65)	Duodenal ulcer	PPI + A + M + Bis	28	NA	80.70%	4	H (RUT, Gram, Clt)	1	5
Novoa-Reyes et al[39]	2014	Peru	140	48.9 ± 12.3 (18-85)	Non-ulcer dispepsia	PPI + A + C	10	NA	72.10%	4	14C, H (H and E)	2	3
Soto et al[40]	2003	Peru	235	37 ± 8.7 (18-55)	Non-ulcer dispepsia	PPI + A + C	14	NA	85.50%	4	14C, H (Warthin-S, Clt)	1.5	5
Leal-Herrera et al[41]	2003	Mexico	467	(> 5)c	Non-ulcer dispepsia	PPI + A + C	14	NA	30.20%	4-6	14C, H (Giemsa, Clt, PCR), Serology	2	4
Mohar et al[42]	2002	Mexico	131	51.4 ± 9.3 (> 40)	Healthy volunteers	PPI + A + C	7	NA	76.30%	6	H (H and E, Elisa), CagA IgG	1	4
Sivapa- lasingam et al[43]	2014	Bolivia	848	(> 6 mo)d	Community populations	PPI + A + C	10	“Triple therapy”	64.00%	6	13C, CagA IgG	1	3
Mera et al[19,44]	2005	Colombia	976	50.8 (29-69)	Intestinal metaplasia	Variable (the majority A + M + Bis)	14	NA	51.60%	156	13C, H (H and E, Steiner)	16	5

^aSix countries were Colombia, Costa Rica, Nicaragua, Chile, Honduras, and 2 sites in Mexico (Sonora and Chiapas);

^bVoluntary treatment;

^c66.7% were > 30 years old;

^d41.2% were > 15 years old. PPI: Proton pump inhibitor; A: Amoxicillin; C: Clarithromycin; H2: H2 Blockers; Bis: Bismuth; Furaz: Furazolidone; C: Urea breath test; H: Histology; RUT: Rapid urea test; Clt: Culture.